RESPIRERX PHARMACEUTICALS INC. (OTCMKTS:RSPI) Files An 8-K Regulation FD Disclosure

RESPIRERX PHARMACEUTICALS INC. (OTCMKTS:RSPI) Files An 8-K Regulation FD Disclosure
Item 7.01 Regulation FD Disclosure

On September 9, 2019, RespireRx Pharmaceuticals Inc. (the “Company”) announced that the Company’s Executive Chairman, Interim Chief Executive Officer, Interim President and Chief Scientific Officer, Arnold S. Lippa, Ph.D., and its Senior Vice President, Chief Financial Officer, Treasurer and Secretary, Jeff E. Margolis, each will be participating as a workshop leader and panel member, respectively at the 2nd Annual International Cannabinoid Derived Pharmaceuticals Summit at the Aloft Boston Seaport District in Boston, Massachusetts. Dr. Lippa is scheduled to participate as a workshop leader at 1:00 p.m. Eastern Time on Tuesday, September 10, 2019, and Mr. Margolis is scheduled to participate as a panel member at 5:30 p.m. Eastern Time on Wednesday, September 11, 2019.

The press release announcing Dr. Lippa’s and Mr. Margolis’s participation in the conference is attached as Exhibit 99.1, which is being furnished and not filed to Item 7.01 of Form 8-K

Item 9.01 Financial Statements and Exhibits

(d) Exhibits.

A list of exhibits that are furnished and filed as part of this report is set forth in the Exhibit Index, which is presented elsewhere in this document, and is incorporated herein by reference.

EXHIBIT INDEX

99.1 Press Release dated September 9, 2019*

* Furnished herewith.


RespireRx Pharmaceuticals Inc. Exhibit
EX-99.1 2 ex99-1.htm   Exhibit 99.1     RespireRx Pharmaceuticals Inc. Executives Participating in the 2nd Annual International Cannabinoid Derived Pharmaceuticals Summit   September 10 – 12,…
To view the full exhibit click here

Story continues below

About RESPIRERX PHARMACEUTICALS INC. (OTCMKTS:RSPI)

RespireRx Pharmaceuticals Inc., formerly Cortex Pharmaceuticals, Inc., is engaged in the discovery, development and commercialization of pharmaceuticals for the treatment of neurological and psychiatric disorders. The Company is focused on the clinical development in the areas of respiratory disorders, including respiratory depression and sleep apnea. It is engaged in research and clinical development of a class of compounds referred to as ampakines, which act to enhance the actions of the excitatory neurotransmitter glutamate at a-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) glutamate receptors. Its ampakines, including CX717, CX1739 and CX1942, were efficacious in treating drug induced respiratory depression caused by opioids or certain anesthetics without offsetting the analgesic effects of the opioids or the anesthetic effects of the anesthetics. Its dronabinol is indicated for the treatment of sleep-related breathing disorders, including sleep apnea.

An ad to help with our costs